|
Jan 08, 2010, 11.04 PM IST
Ranbaxy may be all set to lose its six month exclusivity edge for Nexium, the world's second largest prescription drug with an over USD 5 billion market. According to international media reports, Teva has settled a litigation with AstraZeneca, the innovator of Nexium on the generic version of the drug, reports CNBC-TV18’s Ekta Batra.  Ranbaxy may be all set to lose its six month exclusivity edge for Nexium, the world's second largest prescription drug with an over USD 5 billion market. That's because according to international media reports, it is indicated that Teva has settled a litigation with AstraZeneca, the innovator of Nexium on the generic version of the drug, reports CNBC-TV18’s Ekta Batra.Ranbaxy had settled with AstraZeneca in 2008 for the generic version of Nexium with 180-day exclusivity. Teva has settled with AstraZeneca to launch this drug in May 2014, according to international media reports. However, Ranbaxy had also scheduled the same time of launch i.e. May 2014 for the generic version of Nexium with its 180-day exclusivity. The Teva settlement puts some doubts over whether Ranbaxy can actually adhere to or take part in the 180-day exclusivity that they were granted in the settlement with AstraZeneca. Ranbaxy also has two supply agreements with AstraZeneca for Nexium, for active pharmaceutical ingredients or APIs in 2009 and for formulations in 2010. Ranbaxy’s supply agreement for APIs, which was expected to start in May 2009 is still not underway. Analysts doubt the fact that this delay has caused some concern along with the fact that Teva has settled with AstraZeneca. Ranbaxy’s management declined to comment on the development.
Related News Set email alert for |
Action in Ranbaxy Laboratories
 From DJ EU Officials Spain Aid Cap Of 100 Bn Euros 'should Be Enough'  The latest earning numbers FIRST on CNBC-TV18
News Videos
|
